- White House to Crank Up Pressure on Mortgage Industry
- Treasury Threatens Banks, Not Borrowers
- Dubai World to Restructure About $26 Billion of Debt
- Cramer: Dubai Can’t Sink These 6 Dividend Stocks
- Bove: 26 Banks May Need To Raise More Capital
- Lesson From Dubai: Start Cutting Risk In Your Portfolio
- Iranian Seizure of British Yacht Pushes Oil Above $77
- Should Homeowners Be Able to Stop Paying Mortgage?
- Buffett's Predictions For Next Year—And Every Year
- Treasury Threatens Banks, Not Borrowers
- We're Approaching a Market Bubble: Portfolio Manager
- Hershey Shares: What Options Are Saying
- Nov. 30: Unusual Volume Leaders
- Why Careful Shoppers Are Great for the Box Office
- Blue Nile CEO: 'We're Having the Best Cyber Monday Ever'
- Best Online Retailers to Buy Now: Internet Analyst
- ESPN The Magazine’s Body Issue: A Financial Success
- Cyber Monday: The Last Vestige of Dotcom Hype
MOST SHARED
- Timeless and Time-Tested Warren Buffett Watch Predictions
- Should Homeowners Be Able To Walk Away From Mortgage?
- Goldman Sachs Party Ban: No Gatherings of 12 or More
- Dubai World Set to Restructure About $26 Billion of Total Debt
- Bove: 26 Banks May Need To Raise More Capital
- Notre Dame Fires Charlie Weis After 5 Seasons
- Treasury Threatens Banks, Not Borrowers
- Nov. 30: Unusual Volume Leaders
- Oil Demand Sees Year-Over-Year Rise, First Since 2007
- Blue Nile CEO: 'We're Having the Best Cyber Monday Ever'
Text Size 
Gilead Sciences said on Wednesday its first-quarter profit rose 55% amid higher sales of its drugs for HIV, the virus that causes AIDS.
The biotechnology company said net income rose to $407.4 million, or 85 cents a share, from $262.7 million, or 55 cents a share, a year earlier. Analysts expected a profit of 80 cents a share.
"It's another solid quarter for Gilead ... they keep putting up great numbers," said analyst Michael King of Rodman & Renshaw.
The company continues to expect full-year 2007 drug sales of $3.4 billion to $3.5 billion, Chief Financial Officer John Milligan said on a conference call.
"We would prefer to wait until the end of the second quarter to update the guidance," he said, noting first-quarter sales of anti-fungal drug Ambisome and hepatitis drug Hepsera were stronger than the company had expected.
Total revenue rose 48% to $1.03 billion, exceeding the $992.7 million forecast by analysts.
Sales of HIV drugs rose 56% to $705.1 million, including $345.9 million for the two-drug combination HIV pill Truvada, and $190.2 million for Atripla, a once-daily pill approved by U.S. regulators last July that layers Truvada with Bristol-Myers Squibb's Sustiva.
First-quarter sales of Viread and Emtriva, the two older HIV drugs used in the combination pills, fell 16% to $160.7 million and by 16% to $8.3 million, respectively, as patients switched to the newer treatments.
Hepsera sales rose 35% to $71.3 million, while Ambisome sales rose 14% to $61.5 million.
Foster City, California,-based Gilead also collects royalties on sales by Roche for Tamiflu, an antiviral treatment being stockpiled as a potential treatment for bird flu.
First-quarter royalty and contract revenue more than tripled to $188.2 million, including $167.9 million from Roche for fourth-quarter 2006 Tamiflu sales.
The company said quarterly research and development costs rose to $130.1 million from $88.4 million, while sales and administrative expense rose to $166.6 million from $142.5 million.
Gilead is awaiting a June decision from the U.S. Food and Drug Administration on its application for ambrisentan, a drug developed by Myogen for the treatment of pulmonary arterial hypertension. If approved, the drug could generate annual sales of more than $1 billion, analysts estimate.
Gilead's shares are up more than 21% so far this year, compared with a gain of nearly 8% for the AMEX Biotech Index. The stock, which closed at $78.43, was up slightly in after hours trading.
Print
Email
- Ever wished your cab driver would stop chatting and just get to where you're going? Well, that moment is closer than ever.
- UPS is giving its customers the option to offset its carbon emissions when sending a package.
- Romania's presidential campaign has been rocked by a video that may show the president striking a 10-year-old boy.
- Raising alligators is hard work, and the fickle taste of rich consumers has just made it much harder, says the NY Times.
- A recent issue of ESPN Magazine was one of its top sellers ever, and it only took scantily clad athletes to make it happen.
- The continued real estate boom in China is partially fueled by a generational flood of newlyweds.
Data is a real-time snapshot *Data is delayed at least 15 minutes